CD274 and neoplasm: However, given the overlapping nature of the Basal molecular subtypes and PD-L1-high status to predict sensitivity to ramucirumab, further exploration of these signatures is warranted to identify patient subsets most likely to benefit from anti-angiogenic therapy approaches, as well as anti-angiogenic and PD-1/PD-L1 combination approaches in UC and other tumor types.